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Abstract
Streptococcus pneumoniae (S. pneumoniae) has a multifaceted bond with its
human host and causing several diseases in children and adults when host flexible
immunity and bacterial acquisition factors allow them to invade essentially sterile
spots, such as the middle ear spaces (causes otitis media), lungs (causes pneumo-
nia), bloodstream (causes sepsis) and meninges (causes meningitis). In the early
1940s, management of pneumococcal infections used to be somewhat straightfor-
ward, and penicillin commonly was the antibiotic of choice. Soon after
mainstreaming antibiotic usage, worldwide emergence of antibiotic resistance
among S. pneumoniae isolates has changed this approach. Multiple factors, like prior
antibiotic use, inappropriate usage of antibiotics especially in young age, and day
care attendance are the most commonly identified risk features for the spread of
penicillin resistance and other multiple-antibiotic resistance. Basic fundamental
mechanisms of most pneumococcal resistances have been identified, several orga-
nizations like WHO, CDC, BSAC, EUCAST started campaigns for appropriate anti-
biotic use and also the introduction of pneumococcal conjugate vaccines have been
recommended to limit the further emergence and spread of pneumococcal resistant.
Keywords: drug-resistant S. pneumoniae, World Health Organization,
upper respiratory tract, β-lactam antibiotics, penicillin-binding proteins
1. Background
According to WHO, bacterial resistance to antibiotic drugs are now one of the
most global events that threaten humanity; due to new resistant mechanisms
acquired by bacteria that help them to evade both natural and chemical elimination
systems that are, immune system and antibiotic drugs [1]. With the ability to
acquire resistance, simple infections can create major clinical problems for different
patients, leading to serious events that include death. Unfortunately, although
warnings about the aimless use of antibiotic drugs have been made by medical
experts since the 1940s, the expenditure of antibiotic drugs are still increasing [2].
This issue is not only related to certain countries like India and South Africa where
antibiotics are available without prescriptions, but also worldwide [2]. This implies
that restricted guidelines must be made by specialized health sectors in both hospi-
tals and pharmacies. Not only that but also generating a public awareness forum
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where people around the world are educated about the dangerousness of misusing
antibiotic drugs. However, if increased consumption of antibiotics continues, doors
for bacteria are going to be open, permitting them to enter an adaptive phase where
mutations and among other things can take place; leading to deleterious conse-
quences [3]. Indeed, the world today must reform the way antibiotics are being
prescribed and utilized; not doing so, will impose a fast-rising threat which can be
slowed down if certain behavior changes like a simple hand washing are applied [1].
Nevertheless, researchers in this field are facing a wide range of challenges which
led to a major decrease in the discovery and development of new antibiotics; due to
the widespread use of these drugs which have led to difficult new resistant bacteria
families to appear [4]. This can be illustrated by looking back in time, for instance,
approximately 47 new antibiotics were developed collectively in the period from
1983 to 2002, while from 2003 to 2012 almost seven new drugs only were developed
[4]. This shows how close we are to reaching a post-antibiotic era where fear and
trepidation from the simplest injuries and common infections are once again
established. Therefore, the science community must come together and set up a
focused system where only life-threatening resistant bacterium is targeted in order
to safe major resources and develop better outcomes.
On one hand, we should also not forget to monitor and adjust the public behav-
ior towards this topic, as it is the major fuel to this crisis. On the other hand, if this
threat is left without a serious action, an estimation of nearly 10 million people will
die every year in 2050 due to antimicrobial resistance, not to mention the huge cost
burden with over 100 trillion USD [5]. In this chapter, we aim to establish a
comprehensive understanding of defense mechanism of certain worrying and life-
threatening bacteria (Streptococcus spp.) that have mastered new maneuvers to
evade the immune system and antibiotic drugs; causing multiple of diseases that are
hard to treat, and to investigate its impact on patients clinically. Not only that but
also to scrutinize the general defects that allowed pathogens like bacteria to survive
and conquer the human body, and to explore the drugs that used to fight such
bacteria but eventually failed to do so. Under these circumstances, doors of oppor-
tunities are going to be open for researchers to grasp the most important knowledge
that they need in order to innovate new ideas, to create new treatments and
methods to minimize the risks of this crisis. For this reason, the scope of this chapter
is going to be mainly focused on the problem of certain worrying bacteria that were
categorized and prioritized by WHO.
2. Insights into antimicrobial emergence
It is well-known to scientists that bacteria are one of cleverest creatures that can
not only generate new methods continuously to evade the immune system and
antibiotic drugs, but also adapt to various situations to ensure its survival and
growth. By knowing that, it is important to explore their mechanism in an attempt
to have a better understanding of how they work and function. However, it would
make sense to direct all efforts to certain worrying bacteria that are resistant by
prioritizing it according to certain criteria. To do so, WHO has published a global
priority list of resistant bacteria to antibiotic drugs in order to facilitate a path that
will guide researchers all around the world where the urgency of finding new
treatments is vital [6]. With the help of expert opinion and evidence-based data
WHO-global priority pathogens list developed a multi-criteria decision analysis
(MCDA) technique for prioritizing the research and development of new and
effective antibiotic treatments. Following steps has been taken to set prioritization:
(1) selection of antibiotic-resistant bacteria to be prioritized; (2) selection of criteria
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for prioritization; (3) data extraction and synthesis; (4) scoring of alternatives and
weighting of criteria by experts; and (5) finalization of the ranking of pathogens.
This list was created with the help of specialists all around the world and contains 12
most dangerous resistant bacteria families organized based on where exigency of
new treatments is needed. The first three were sat as a critical priority, and those
are Acinetobacter baumannii, CR, Pseudomonas aeruginosa CR and Enterobacteriaceae
3GCR [6]. The second six were sat as high priority, and those are Enterococcus
faecium VR, Staphylococcus aureusMR&VR, Helicobacter pylori ClaR, Campylobacter
FQR, Salmonella spp. FQR andNeisseria gonorrhoeae FQR [6]. The last three were sat
asmedium priority, and include S. pneumoniae PNS, Haemophilus influenzae AmpR
and Shigella spp. FQR [6]. It is important to say that WHO has clearly pinpointed
thatMycobacterium tuberculosis was excluded from the list because it has been
reported worldwide as a priority and other initiatives are already devoted to finding
new treatments forMycobacterium tuberculosis [7]. In spite of that, those bacteria
were selected based on 10 criteria, and those include “mortality, healthcare and
community burden, a prevalence of resistance, a 10-year trend of resistance, trans-
missibility, preventability in the hospital and community settings, treatability and
current pipeline” [8]. Each criterion was chosen by experts who have previous
experience and knowledge, and evidence for those criteria was taken from various
reliable sources; such as, systematic reviews of published literature and so much
more. In the light of this, a one must bear in mind that sometimes establishing
priorities have its drawbacks, which a large public forum like WHO should seek to
abstain to avoid any wrongness that would rather cause a disaster; however, it is
indeed an appreciated and understandable move as sometimes “the simplest mes-
sages are usually the most effective,” and it will eventually help in addressing
bacteria in a proper manner [9]. Nonetheless, the goal here is not only to create new
treatments, but rather bring multiple sectors like governments, pharmaceutical
companies, and experts together to ensure a successful procedure to face this
great challenge both by raising awareness of communities and encouraging
research [10, 11].
Furthermore, to face a great challenge like bacterial resistance a one must have a
tremendous knowledge about their defense mechanism and the way they behave
towards facing obstacles that are immune system and antibiotic drugs, and we
attempt to review the accessible evidence and asses the relative importance of
pathogens, and the status of drug-resistance S. pneumoniae, and their mechanisms
and evolution of resistance to the various antibiotics.
3. Streptococcus pneumoniae
3.1 Classification, transmission, colonization and invasion
S. pneumoniae, is an important facultatively anaerobic Gram-positive coccal-
shaped bacterium that occur in pairs or chains and surrounded by a polysaccharide
capsule, belongs to Firmicutes phylum. Traditionally, classification based on their
three distinctive patterns appear on blood agar, which are termed alpha (partial),
beta (complete) and gamma (none) hemolysis. According to Rebecca Lancefield
classification, the beta-hemolytic streptococci (BHS) species can be further classi-
fied by the cell wall carbohydrate [12]. Most of the BHS species are associated with
human diseases, and are categorized under Lancefield Groups A, B, C and G. Group
A and Group B are characterized by presence of antigen on particular species while
Group C and G antigen occur on a small number of closely related species (collec-
tively as termed “Group C/G”) [13] (Figure 1). S. pneumoniae (also known as
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pneumococcus) is an opportunistic pathogen that colonizes the mucosal surfaces of
the human upper respiratory tract (URT) and group in other species of streptococci.
This microorganism survives and multiply in wet environments, colonize in respi-
ratory tract, bloodstream, pleural fluid, peritoneum, surgical wounds and orophar-
ynx secretions of infected individuals. It has also been shown to colonize the
normally sterile site results in invasive infection. Despite the diversity of host sites
of S. pneumoniae can survive for long periods on both dry and moist surfaces.
Carriage of pneumococci in the nasopharynx is more common in young children.
Carriage is generally asymptomatic; but it serves as the main source for invasive
pneumococcal infections and also plays a role in transmission from person-to-
person. Adherence is the main features that facilitate colonization in the host cells
and tissues. Prerequisite factors (including influenza A virus and other bacteria) are
required for S. pneumoniae to colonize and persist on the mucosal surface, after
attaining of incubation duration sufficient transmission to occur. Nasal inflamma-
tory response due to influenza A virus, that regulates the expression of pro-
inflammatory chemokines, also upregulation of target epithelial receptors and
damaged respiratory epithelium used for S. pneumoniae adherence and disintegrate
the epithelium and that helps in providing nutrient. These combined effects of viral
co-infection increase the susceptibility of the host to colonization of S. pneumoniae
[14]. S. pneumoniae basically produced two enzymes, peptidoglycan-N-
acetylglucosamine deacetylase and attenuator of drug resistance, that helps in the
modification of their peptidoglycan and promote it resistant to the lytic effects of
lysozyme, which are abundant on the mucosal surface of the upper respiratory tract
[15]. Negatively charged capsular polysaccharides also aided S. pneumoniae access
and attach to the surface of epithelial cells and avoiding entrapment in the nasal
mucus [16]. S. pneumoniae also uses several surface components for binding, like
virulence protein A & B, enolase, phosphorylcholine moieties on cell wall teichoic
acid [17, 18]. The successful colonization of S. pneumoniae depends on their rela-
tionship with normal microbiota, which are very complex mechanism. Symbiotic
relation with microbiota of nasopharynx is depends on competition or coordination
in nature [19]. S. pneumoniae produces numbers of bacteriocins (pneumocins) and
other related microbial peptides which helps in inhibit the growth of another
microbiota [20].
3.2 Identified risk features of S. pneumoniae
Over the last 15 years, S. pneumoniae, designated as a “red-alert” human
pathogen, primarily because of its exceptional ability to survive in the community
environment and remarkable ability to upregulate or acquire resistance to antibi-
otics. S. pneumoniae imposes a huge disease burden as the leading cause of wide
Figure 1.
Classification of Streptococcus spp. and drug of choice for causative agents.
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range of infections, including community-acquired pneumonia, meningitis and
sepsis in children and adults and causes otitis media in infants and young children.
As all of these diseases are “dead ends” in the life cycle of the organism, the bacterial
factors that cause invasive diseases must also be adaptive for colonization and/or
transmission. S. pneumoniae is an opportunistic pathogen that colonizes the mucosal
surfaces of the human upper respiratory tract. Up to 27–65% of children and <10%
of adults are carriers of S. pneumoniae and carriage involves a commensal relation-
ship between the bacterium and the host [21]. Dissemination of this microorganism
through local spread, aspiration or seeding to the bloodstream results in many
invasive diseases (Figure 2). Globally, pneumonia considered as leading cause of
death in younger child whose age is <5 years, and it attributed 1.6 million deaths
annually. According to the World Health Organization, pneumococcal disease con-
tinues to cause the most deaths among vaccine-preventable diseases [22]. Persons at
higher risk for invasive pneumococcal disease include children below 2 years of age,
adults above 65 years of age, those with underlying chronic conditions (cardiovas-
cular or pulmonary diseases, etc.), and also who are immunocompromised like,
congenital immunodeficiency, human immunodeficiency virus infection, leukemia,
or systemic corticosteroid use, etc. [23].
3.3 Mechanisms of antimicrobial resistance
An organism is considered resistant when its growth in vitro is not inhibited by
an antimicrobial agent. The causative agents for resistance differ greatly but often
linked to empirical antimicrobial therapy, that’s include inappropriate
Figure 2.
Pathophysiology of Streptococcus pneumoniae.
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administration of subtherapeutic doses of antimicrobial agents, drug overuse or
interrupted courses, and poor tissue-intake of the antimicrobial agent [24].
Antimicrobial resistance probably originated from horizontal resistance gene
between bacterial species. These genes are acquired rapidly by the mechanism of
plasmid promoted-conjugation, transformation or virus-induced transduction pro-
cess, that all process contribute to the development of antimicrobial resistance.
Due to these mechanisms some of the genes are inherited, some change to random
DNA mutations in bacteria, and others are imported from related or distant bacte-
ria [25] (Figure 3). Repeatedly use of antibiotic has been shown to be the strongest
risk factor for the carriage and spread of resistant pneumococci, at both the
individual and the community levels [26]. Evidence showed that antimicrobial
resistance developed in S. pneumoniae may indication of transmission of the
organism among patients and may be predictive of an impending outbreak of
S. pneumoniae infections.
S. pneumoniae modify its genome through the uptake and incorporation of
exogenous DNA from other pneumococci or closely related oral streptococci has
facilitated the spread of antibiotic resistance and evasion of vaccine-induced
immunity. Identification of resistant pneumococci based upon genetic features,
culture-based phenotypic susceptibility methods are the gold-standard approach in
clinical laboratories. Interpretations to evaluate antibiotic resistance in S.
pneumoniae have been established by several organizations, such as WHO, CDC,
Clinical and Laboratory Standards Institute (CLSI), the (BSAC), British Society for
Antimicrobial Chemotherapy (BSAC), and the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST). Culture of clinical specimens and subsequent
antibiotic susceptibility testing to suggest treatment options are helps in recognition
of antibiotic resistance in S. pneumoniae. The microbial identification and diagnosis
of the infecting microorganisms are prerequisites for efficient treatment and
hospital/community infection control and helps in control the spreading antibiotic
resistance strains. These procedures are time consuming, laborious, and require
well-trained technicians for correct interpretation of results. However, effective,
immunological microbial identification methods have been developed for only a
small number of bacterial species [27]. Molecular-based methods such as ribosomal
RNA sequencing and MALDI-TOF are available and considered as powerful tool to
Figure 3.
Bacterial acquiring resistance genes. Three major methods for resistant gene acquisition: (1) donor cells transfer
plasmid containing one or more genes into another bacteria, (2) bacteria integrate gene through transformation
process and, (3) a virus acquires a resistance gene from a bacterium and injects it into a different bacterial cell.
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improve detection from clinical specimens [28, 29]. Biomolecular factors for anti-
biotics resistance have also led to the development of a variety of molecular assays
to detect the presence of resistance genes in pneumococcal isolates (PCR) and also
directly from clinical specimens (MALDI-TOF) [30, 31]. According to Metcalf
et al., they developed a promising whole-genome sequencing (WGS) based “typing
pipeline” for rapid automated predictions of pneumococcal serotypes, MICs, geno-
types, and additional features [32]. Enhanced bioinformatic tools such as ARG-
ANNOT (antibiotic resistance gene annotation) for querying WGS data greatly
expand the depth of laboratory-based strain surveillance efforts and provides a
periodically updated database for known accessory resistance genes to screen bac-
terial whole-genome sequence data [33].
Antibiotics have been a basis of pneumococcal disease treatment and either by
decreasing or eradicating the bacterial load from host body [34]. As production of
penicillin started in the mid-1940s, after that treatment of pneumococcal infections
has relied heavily upon penicillin and other β-lactam antibiotics, which showed
most effective antibiotics against this bacterium. In 1912, a first antimicrobial-
resistant pneumococcal infections were documented when optochin resistance in
experimental mice was described [35]. Five years later acquired optochin resistance
was seen in humans [36]. In 1967, the first clinical isolate in a pediatric patient in
Australia reported with reduced penicillin susceptibility [37]. During the period of
1970–1980, pneumococci resistant to penicillin, erythromycin, and trimethoprim-
sulfamethoxazole (TMP-SMX) spread rapidly globally, including many developed
nations [38]. Tetracycline, chloramphenicol and fluoroquinolone resistances were
also documented at relatively low levels compared to those for the above-
mentioned antibiotics [39]. More than 40% of isolates are penicillin resistant in
several countries that lack significant conjugate vaccine coverage [40, 41]. Only few
studies have been conducted on the acquisition of multidrug resistance however,
these studies have found that extremes of age (i.e., <5 years and more than 65 years
of age), previous use of β-lactam antibiotics by patients with noninvasive disease,
antibiotic use in the last month by patients with nasopharyngeal colonization,
population density, geographic location, and pneumococcal seven-valent conjugate
vaccine (PCV7) serotype are all independent risk factors [42].
Typical therapy for the treatment of pneumococci disease (including invasive)
are β-lactam antibiotics (benzylpenicillin, amoxicillin or ampicillin). Soon after
mainstreaming antibiotic usage, multi-resistant pneumococcal clones emerged and
disseminated worldwide. Penicillin resistant S. pneumoniae strains emerged glob-
ally, including macrolide and tetracycline, that elucidates the potential of this
microorganism to respond selectively in environmental changes. Regulated mecha-
nisms of innate resistance or acquisition of foreign determinants that have also
brought S. pneumoniae as one of the organisms threatening the current antibiotic
era. Nearly, 90 serotypes of S. pneumoniae have been identified like 6B, 9V, 14, 19F,
or 23F were high level resistant to β-lactam, were first reported in children via
nosocomial transmission [43]. In European Union countries, multidrug resistance
was observed among isolates of serotypes 19A, 14, 1, 19F, and 23F [44]. In the
United States, serotypes of 15A, 15B, 15C, 6C, 23A and 35B showed less multidrug
resistance if the person had conjugate vaccine, taken 14 years ago. Multi-resistant
serotype 19A isolates still showed the highest MICs for β-lactams, macrolides,
lincosamides, tetracycline, and co-trimoxazole [45].
Another cause of β-lactam resistance is due to phenotypic expression of penicil-
lin resistance alterations that results in modification of penicillin-binding proteins
(PBPs), consequently reducing peptidoglycan synthesis. This loose affinity causes
cell lysis and bacterial cell death [46]. As peptidoglycan serves important roles in
maintenance of cell integrity, cell expansion, cell division, cellular diffusion and
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surface anchoring. Gram positive bacterium pneumococcal peptidoglycan is com-
posed of alternating glucosamine and N-acetylmuramic acid residues, directly
cross-linked by transpeptidases between two N-acetylmuramic acid residues via
short pentapeptides (L-Ala-γ-D-Glu-L-Lys-D-Ala-D-Ala) between the L-Lys and
the last D-Ala of an adjacent loop. Structural similarity of the β-lactam binds to the
D-Ala-D-Ala terminus of the peptidoglycan stem peptide, that causes β-lactams
irreversibly bind transpeptidases at their active site. Binding of β-lactams to the
transpeptidase active site of these penicillin-binding proteins (PBPs) thus blocks
cross-linking of muropeptide chains to prevent cell wall synthesis [47]. Pneumo-
coccal strain reveals reflective changes in corresponding key PBP genes, and a very
wide range of “resistant” PBP gene alleles [48]. It has never been observed within
pneumococcal strains how β-lactamases, introduced either mobile genetic elements
or expressed from the core genome. Structural alterations that causes prevention of
binding to analogs (β-lactams) of their normal substrates is expressed from the core
genome serve their essential biosynthesis for resistant PBP [49].
Six PBPs genes have been described in S. pneumoniae. Three PBP alterations
(PBP1a, 2x, and 2b) strongly associated with β-lactam resistance. All three of these
PBPs share a penicillin-sensitive N-terminal transpeptidase domain that contains
three conserved motifs: SerXXLys, containing the active-site serine that is bound
(acylated) by PBPs; SerXAsn; and LysSer(or Thr)Gly [50]. In contrast to PBP2b and
PBP2x, PBP2a has been associated with decreased susceptibility and higher MICs
which causes β-lactam resistance [51]. PBP gene substitutions that appear to affect
the polarity, charge distribution, and flexibility of the region neighboring the active
site to decrease PBP-binding affinities for penicillin and/or other β-lactam classes in
non-susceptible pneumococci [52].
As discussed earlier, PBP genes (PBP1a, PBP2b, and PBP2x) have been clearly
demonstrated to be required for high-level β-lactam resistance in clinical isolates. In
some instances, low-level resistance is also dependent upon proteins that are not
directly targeted by β-lactams. Sometime due to different PBP allele combinations
shows different β-lactam resistance phenotypes, and this complication leads to PBP
genes from certain strains were not transform wild-type strains to the same high
level of resistance [53]. One study showed that strains exhibiting identical PBP
transpeptidase domain sequences exhibited penicillin MICs ranging from 0.25 to
2.0 μg/ml [54]. Another cause for resistivity is due to unaltered murM genes. murM
gene inactivation, effects in the lack of branching activity, subsequently the
synthesis of peptidoglycan consisting of only linear muropeptides. The finding
suggested that MurM aminoacyl ligase appears to be required for penicillin
resistance, that appeared a direct role of aminoacyl ligase branching activity in
penicillin resistance [55]. One study also showed another type of resistant mecha-
nism, peptidoglycan O-acetyltransferase encoded by the adr gene, attenuates PBP
variant causes penicillin resistance [56]. Though, recent studies showed that most
penicillin-resistant pneumococci are effectively treated by high doses of parenteral
β-lactams.
4. Conclusion
With the advent of more advanced laboratory techniques, including whole-
genome sequencing, and continued, high-quality surveillance of antimicrobial
resistance, we can continue to further expand our understanding of this area.
Special program and campaigns run by various organization like, WHO, CDC,
BSAC, EUCAST should continue to be in all countries to decrease not only the
burden of disease but also antimicrobial-resistant pneumococci. Also more focus
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on pneumococcal conjugate-vaccines because the new conjugate vaccines target
these resistant serotypes, the implementation of use of these vaccines is expected
to have an important role in limiting the spread of antibiotics-resistant
S. pneumoniae strains.
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